Pipeline

Product

Pre-clinical

Phase I

Phase II

MB-101 IL13Rα2-specific CAR

Glioblastoma

68%

MB-102 CD123 CAR

Acute Myeloid Leukemia & Blastic Plasmacytoid Dendritic Cell Neoplasm

63%

MB-103 HER2 CAR

Glioblastoma Multiforme

52%

MB-104 CS1 CAR

Multiple Myeloma

40%

MB-105 PSCA CAR

Prostate, Pancreatic, Gastric & Bladder Cancers

40%

MB-106 CD20 CAR

B-cell non-Hodgkin Lymphoma

63%

MB-107 XSCID Gene Therapy

X-linked Severe Combined Immunodeficiency

78%